West Pharmaceutical Services Updates Full-Year 2024 Adjusted EPS Guidance To $6.55-$6.75 Compared To Prior Guidance Of $6.35-$6.65 And Consensus Of $6.51
Portfolio Pulse from Benzinga Newsdesk
West Pharmaceutical Services has updated its full-year 2024 adjusted EPS guidance to a range of $6.55-$6.75, which is an increase from the previous guidance of $6.35-$6.65 and above the consensus estimate of $6.51.
October 24, 2024 | 10:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
West Pharmaceutical Services has increased its full-year 2024 adjusted EPS guidance to $6.55-$6.75, higher than both its previous guidance and the consensus estimate.
The increase in EPS guidance suggests improved financial performance expectations, which is likely to positively impact the stock price. The new guidance exceeds both the previous range and the consensus estimate, indicating strong company performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100